GENMAB A/S/S (GMXAY) Stock Price, News & Analysis

Company Overview

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing antibody-based medicines for cancer and other serious diseases. The company develops therapies using technologies such as its DuoBody bispecific antibody platform and HexaBody antibody technology, which are designed to engage immune mechanisms and target disease-related cells.

Genmab’s commercial and partnered portfolio includes DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY or TEPKINLY (epcoritamab) for certain B-cell lymphomas, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen, now part of Pfizer. The company also has a history of developing ofatumumab, marketed by Novartis as Kesimpta for multiple sclerosis, and Arzerra for certain blood cancers.

Founded in 1999, Genmab operates through research, development and commercial collaborations with pharmaceutical companies and serves patients and healthcare markets internationally. Its activities include antibody discovery, clinical development, regulatory support and the commercialization of selected products, with revenue also generated through licensing arrangements, royalties and collaboration agreements. Genmab is led by Chief Executive Officer Jan van de Winkel, who has been associated with the company since its early development.

Key Stats

• Today's Range: $39.64 to $44.34
• 50-Day Range: $31.94 to $40.00
• 52-Week Range: $12.10 to $19.00
• Volume: 13.00 million shs
• Average Volume: 48,553 shs
• Market Capitalization: N/A
• P/E Ratio: 16.81
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:GMXAY
• CIK: N/A
• Web: www.genmab.com
• Phone: 45 70 20 27 28
• Fax: N/A
• Employees: 1,660
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 16.81
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A